← All trials
NCT05905068
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2023
- Primary completion
- Jul 27, 2024
- Completion date
- Jul 27, 2024
- First posted
- Jun 15, 2023
- Last posted
- Aug 22, 2023
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IkariaLead sponsor
- Nucleus Network LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.